recurrence

  •   George Lundberg, MD

    Research paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    There has been confusion about how to conduct follow-up for a patient with lung cancer who has received therapy intended to cure. This new guideline intends to clarify best practice.

    Go to full paper published in the Journal of Clinical Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    Cancer of the urinary bladder is common, commonly recurs, and can be fatal. To learn more, read this up-to-date, comprehensive, unbiased, and balanced report from Medscape.
  •   George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:

    Most prostate cancers don’t hurt the patient. Surgery for high-risk prostate cancer can be beneficial. If the cancer recurs, more treatment could be helpful. This study provides useful information about detection of recurrence.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

     

  •   Emma Shtivelman, PhD

    Excerpt:

    “Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium.

    “Data from the Phase III KATHERINE study show that Kadcyla (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death by 50% compared to Herceptin (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual disease following neoadjuvant therapy.”

    Go to full article published by PharmaTimes on Dec 6, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   Emma Shtivelman, PhD

    Excerpt from Healio:

    “An online prognostic tool accurately determined the risk for late distant recurrence among women with ER-positive breast cancer, according to a single-arm, prospective study.

    “The Clinical Treatment Score post-5 years (CTS5) tool could be used to determine whether patients should continue endocrine therapy 5 years after initial treatment.”

    Go to full article published by Healio on Sep 19, 2018.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.